A hand-pick of latest VHIO research highlights aimed at the more precise diagnosis of familial breast and ovarian cancer

by VHIO

​The BRCA1 and BRCA2 genes are crucial actors in the DNA damage response and repair pathway; a function that is critical in preserving the integrity of the genome. Mutations that meddle with the nor...

Read more

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer

by CNIO - Centro Nacional de Investigaciones Oncológicas

Published in the Journal of Clinical Oncology, the study has potential implications for families with members suffering from these two types of tumours who are at an increased risk of developing cance...

Read more

Phase III trial with PM1183 in ovarian cancer (CORAIL) continues on the basis of positive recommendation by IDMC

by Pharmamar Zeltia

The IDMC's recommendation came after an analysis of the safety data obtained with the first 80 patients treated in the trial. This pivotal randomised Phase III trial assesses the efficacy of PM1183 co...

Read more

Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors

by Myriad Genetics Iberia

Myriad is actively collaborating with leading pharmaceutical companies to develop Tumor BRACAnalysis CDx as a companion diagnostic for use with certain PARP inhibitors, platinum-based drugs and other ...

Read more

Myriad Receives FDA Approval of BRACAnalysis CDx as Companion Diagnostic for Lynparza in Ovarian Cancer Patients

by Myriad Genetics Iberia

Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor for patients with germline mutations in BRCA1/2 advanced ovarian cancer who have had three or more lines of chemotherapy

Read more

PharmaMar´s antitumor agent PM1183 significantly improves overall survival compared with standard therapy in patients with resistant/refractory ovarian cancer

by Pharmamar Zeltia

PharmaMar´s antitumor agent PM1183 significantly improves overall survival compared with standard therapy in patients with resistant/refractory ovarian cancer

Read more

Positive survival data from a randomized Phase II trial with PM1183 in platinum resistant ovarian cancer will be presented at ASCO

by Pharmamar Zeltia

​New clinical trial data from both Yondelis® and PM1183 have been selected by The American Society of Clinical Oncology (ASCO) for oral presentations

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New advances in cancer viral immunothera...

by Universitat de Barcelona

It has been developed a new strain of vaccinia virus, which can replic...

Photos Stream